Windlas Biotech's Q2 FY 2025-26 Quarterly Results

Result Summary

• Windlas Biotech Ltd reported a 5.0% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a growth of 17.8%.
• Its expenses for the quarter were up by 5.4% QoQ and 18.0% YoY.
• The net profit increased 0.8% QoQ and increased 13.7% YoY.
• The earnings per share (EPS) of Windlas Biotech Ltd stood at 8.48 during Q2 FY 2025-26.

Financial Statments for Q2 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Windlas Biotech Ltd specializes in the pharmaceutical manufacturing sector, primarily focusing on the development and production of generic pharmaceutical formulations. The company operates within the broader healthcare industry, contributing to the availability of cost-effective medication solutions. Although specific recent developments are not provided here, companies within this sector typically engage in activities related to regulatory approvals, product launches, and expansion of manufacturing capacities. Windlas Biotech Ltd's operations are likely aligned with these industry trends, aiming to enhance their market presence and product offerings.

Revenue

During the second quarter of the fiscal year 2026 (Q2FY26), Windlas Biotech Ltd reported a total income of ₹226.04 crores. This represents a quarter-over-quarter (QoQ) increase of 5.0% from ₹215.33 crores in Q1FY26. Year-over-year (YoY), the total income saw a significant increase of 17.8% compared to ₹191.84 crores in Q2FY25. This growth in revenue reflects the company's ongoing ability to enhance its income streams over both the short and long term. The increases in revenue could be attributed to factors such as expanded product offerings, improved market penetration, or other operational efficiencies.

Profitability

In Q2FY26, Windlas Biotech Ltd's profit before tax amounted to ₹23.59 crores, marking a 1.4% QoQ increase from ₹23.26 crores in Q1FY26 and a 16.3% YoY rise from ₹20.29 crores in Q2FY25. The tax expense for the quarter was ₹5.79 crores, up by 3.6% QoQ from ₹5.59 crores and 25.1% YoY from ₹4.63 crores. Consequently, the profit after tax reached ₹17.80 crores, showing a modest QoQ growth of 0.8% from ₹17.66 crores and a 13.7% YoY increase from ₹15.66 crores. Earnings per share were reported at ₹8.48, with a 1.7% QoQ rise from ₹8.34 and a 14.1% YoY growth from ₹7.43. These figures indicate improvements in profitability metrics over the periods.

Operating Metrics

Windlas Biotech Ltd's total expenses for Q2FY26 were ₹202.46 crores, which represents a 5.4% increase from ₹192.08 crores in Q1FY26 and an 18.0% rise from ₹171.55 crores in Q2FY25. The increases in expenses are consistent with the revenue growth, suggesting that the company's operational scale is expanding. Despite the rise in expenses, the company maintained a growth in profitability, as evidenced by the higher profit before tax and profit after tax figures. The financial data suggest that Windlas Biotech Ltd is managing its expenses in line with revenue growth, which may reflect efficient operational strategies.